Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein) The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.
Conditions Studied
Interventions
- DRUG Elranatamab
- DRUG Carfilzomib
- DRUG Maplirpacept
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center - Aventura — Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs — Coral Springs
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach
- Sylvester Comprehensive Cancer Center - Hollywood — Hollywood
- Griffin Cancer Research Building (GCRB) — Miami
- Sylvester Comprehensive Cancer Center — Miami
- University of Miami Hospital and Clinics — Miami
- Sylvester Comprehensive Cancer Center - Kendall — Miami
- Sylvester Comprehensive Cancer Center - Plantation — Plantation
California
- Beverly Hills Cancer Center — Beverly Hills
- Clinical Research Advisors (Encino Satellite Location) — Encino
- Clinical Research Advisors (Korea Town Satellite Location) — Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location) — Los Angeles
Georgia
- Emory University Hospital Midtown — Atlanta
- Emory University Administration Office — Atlanta
- Emory University Hospital — Atlanta
- Winship Cancer Institute — Atlanta
Arkansas
- University of Arkansas for Medical Sciences — Little Rock
Iowa
- State University of Iowa, Division of Sponsored Programs — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05675449
The ClinicalTrials.gov registry entry for NCT05675449 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions — of which Elranatamab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05675449 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Florida, California, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05675449 about?
NCT05675449 is a clinical study titled "A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma". The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination wi...
What is the current status of trial NCT05675449?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-12-14. Estimated completion is 2028-02-29.
What conditions does trial NCT05675449 study?
This clinical trial studies the following conditions: Multiple Myeloma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05675449?
The interventions under investigation include: Elranatamab (DRUG), Carfilzomib (DRUG), Maplirpacept (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05675449?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05675449 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.